Life Science Investing

We are Abingworth, a transatlantic bioscience investment firm with a deep understanding of both the science and markets we invest in.

Explore our Portfolio

For over 30 years, Abingworth has been working alongside entrepreneurs to develop their ideas into products that have a dramatic impact on health. With a broad transatlantic approach to backing innovation, we invest in drugs, devices and diagnostics from seed-stage start-ups to publicly traded companies.

1.9B raised in life science funds
64 IPOs
11 life science funds raised

The Abingworth Difference

Collaborate

From decades of experience, we understand that one of the keys to building a great company is true partnership between entrepreneurs and their investors.

Innovate

Helping clever and committed people turn scientific breakthroughs into significant new advances in healthcare? We can’t imagine many more rewarding endeavours.

Create

By harnessing advances in life sciences, we have built a succession of companies and helped to create one of the world’s most vibrant and important industries.

Our Portfolio

Our longstanding commitment to partnering with entrepreneurs is evident throughout our portfolio. From T-cells to inflammasomes, gene editing to gene therapy, conjugate vaccines to novel antibiotics, we invest in a broad range of cutting-edge approaches. We also invest in small later-stage biotech companies, including some that are publicly traded, and in clinical co-development programmes with major pharmaceutical firms.

Our Team

Collectively, the Abingworth team has many decades of experience in almost every aspect of starting and growing a biotech company. Whatever the challenge - creating your company, building your team, developing your strategy, advancing your programmes, negotiating with big pharma - our partners and advisors will be there to help you.